Collaboration in pharmacovigilance: lamotrigine and fatal severe cutaneous adverse reactions – a review of spontaneous reports
Neil Brickel,1 Haris Shaikh,1 Andrew Kirkham,2 Greg Davies,1 Michelle Chalker,1 Pascal Yoshida3 1Global Clinical Safety and Pharmacovigilance, GlaxoSmithKline, Uxbridge, Middlesex, UK; 2Classic and Established Products, GlaxoSmithKline, Brentford, Middlesex, UK; 3Clinical Safety and Post-marketing...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-07-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/collaboration-in-pharmacovigilance-lamotrigine-and-fatal-severe-cutane-peer-reviewed-article-TCRM |
| _version_ | 1818838358604906496 |
|---|---|
| author | Brickel N Shaikh H Kirkham A Davies G Chalker M Yoshida P |
| author_facet | Brickel N Shaikh H Kirkham A Davies G Chalker M Yoshida P |
| author_sort | Brickel N |
| collection | DOAJ |
| description | Neil Brickel,1 Haris Shaikh,1 Andrew Kirkham,2 Greg Davies,1 Michelle Chalker,1 Pascal Yoshida3 1Global Clinical Safety and Pharmacovigilance, GlaxoSmithKline, Uxbridge, Middlesex, UK; 2Classic and Established Products, GlaxoSmithKline, Brentford, Middlesex, UK; 3Clinical Safety and Post-marketing Surveillance, GlaxoSmithKline KK, Tokyo, Japan Abstract: Pharmacovigilance presents many challenges, particularly when managing unpredictable, rare conditions, eg, severe cutaneous adverse reactions (SCARs). Such rare events are often only detected from spontaneous reports, which present their own limitations, particularly during a prolonged global launch schedule. GlaxoSmithKline’s routine pharmacovigilance includes regular reviews of global adverse event (AE) reports and aggregate data from a central safety database. Lamotrigine is one of the several antiepileptic drugs associated with SCARs. After identification of increased rates of fatal SCAR cases with lamotrigine in Japan between September and December 2014, this analysis investigated the global incidence of fatal SCARs with lamotrigine and explored whether known risk factors may have contributed to these cases. Global fatal SCAR cases reported with lamotrigine administration from launch until January 2015 were reviewed for evidence of temporal association with dosing and the presence of risk factors, including comorbidities, concomitant medications, and noncompliance with the prescribing information (PI). Worldwide, the estimated cumulative exposure to lamotrigine was >8.4 million patient-years. Globally, there were 54,513 AE reports for lamotrigine, of which 3,454 (6.3%) concerned SCARs. Of these, 122 (3.5%) had a fatal outcome (attributable and nonattributable to lamotrigine), equating to 0.01 fatal SCARs per 1,000 patient-years. In Japan (estimated cumulative exposure 141,000 patient-years), 17 fatal SCARs were reported (attributable and nonattributable), equating to 0.12 per 1,000 patient-years. Seventy-one percent of fatal SCAR cases in Japan showed evidence of noncompliance with the recommended dosing regimen; in 65% of the cases, a delay in discontinuation of lamotrigine after early signs of hypersensitivity was reported. Despite a number of limitations inherent in comparing spontaneous report data, this analysis highlights the need for adherence to the lamotrigine PI and emphasizes the importance of collaboration between global and local pharmacovigilance departments, to promptly identify and reduce the risk of rare and serious events, such as SCARs. Keywords: antiepileptic drug, pharmacovigilance, Stevens–Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms |
| first_indexed | 2024-12-19T03:37:08Z |
| format | Article |
| id | doaj.art-64683f01df624b3a838d0486fea4c989 |
| institution | Directory Open Access Journal |
| issn | 1178-203X |
| language | English |
| last_indexed | 2024-12-19T03:37:08Z |
| publishDate | 2017-07-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Therapeutics and Clinical Risk Management |
| spelling | doaj.art-64683f01df624b3a838d0486fea4c9892022-12-21T20:37:21ZengDove Medical PressTherapeutics and Clinical Risk Management1178-203X2017-07-01Volume 1389790333880Collaboration in pharmacovigilance: lamotrigine and fatal severe cutaneous adverse reactions – a review of spontaneous reportsBrickel NShaikh HKirkham ADavies GChalker MYoshida PNeil Brickel,1 Haris Shaikh,1 Andrew Kirkham,2 Greg Davies,1 Michelle Chalker,1 Pascal Yoshida3 1Global Clinical Safety and Pharmacovigilance, GlaxoSmithKline, Uxbridge, Middlesex, UK; 2Classic and Established Products, GlaxoSmithKline, Brentford, Middlesex, UK; 3Clinical Safety and Post-marketing Surveillance, GlaxoSmithKline KK, Tokyo, Japan Abstract: Pharmacovigilance presents many challenges, particularly when managing unpredictable, rare conditions, eg, severe cutaneous adverse reactions (SCARs). Such rare events are often only detected from spontaneous reports, which present their own limitations, particularly during a prolonged global launch schedule. GlaxoSmithKline’s routine pharmacovigilance includes regular reviews of global adverse event (AE) reports and aggregate data from a central safety database. Lamotrigine is one of the several antiepileptic drugs associated with SCARs. After identification of increased rates of fatal SCAR cases with lamotrigine in Japan between September and December 2014, this analysis investigated the global incidence of fatal SCARs with lamotrigine and explored whether known risk factors may have contributed to these cases. Global fatal SCAR cases reported with lamotrigine administration from launch until January 2015 were reviewed for evidence of temporal association with dosing and the presence of risk factors, including comorbidities, concomitant medications, and noncompliance with the prescribing information (PI). Worldwide, the estimated cumulative exposure to lamotrigine was >8.4 million patient-years. Globally, there were 54,513 AE reports for lamotrigine, of which 3,454 (6.3%) concerned SCARs. Of these, 122 (3.5%) had a fatal outcome (attributable and nonattributable to lamotrigine), equating to 0.01 fatal SCARs per 1,000 patient-years. In Japan (estimated cumulative exposure 141,000 patient-years), 17 fatal SCARs were reported (attributable and nonattributable), equating to 0.12 per 1,000 patient-years. Seventy-one percent of fatal SCAR cases in Japan showed evidence of noncompliance with the recommended dosing regimen; in 65% of the cases, a delay in discontinuation of lamotrigine after early signs of hypersensitivity was reported. Despite a number of limitations inherent in comparing spontaneous report data, this analysis highlights the need for adherence to the lamotrigine PI and emphasizes the importance of collaboration between global and local pharmacovigilance departments, to promptly identify and reduce the risk of rare and serious events, such as SCARs. Keywords: antiepileptic drug, pharmacovigilance, Stevens–Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptomshttps://www.dovepress.com/collaboration-in-pharmacovigilance-lamotrigine-and-fatal-severe-cutane-peer-reviewed-article-TCRMAnti-epileptic drugpharmacovigilanceStevens-Johnson syndrometoxic epidermal necrolysisDrug Reaction with Eosinophilia and Systemic Symptoms |
| spellingShingle | Brickel N Shaikh H Kirkham A Davies G Chalker M Yoshida P Collaboration in pharmacovigilance: lamotrigine and fatal severe cutaneous adverse reactions – a review of spontaneous reports Therapeutics and Clinical Risk Management Anti-epileptic drug pharmacovigilance Stevens-Johnson syndrome toxic epidermal necrolysis Drug Reaction with Eosinophilia and Systemic Symptoms |
| title | Collaboration in pharmacovigilance: lamotrigine and fatal severe cutaneous adverse reactions – a review of spontaneous reports |
| title_full | Collaboration in pharmacovigilance: lamotrigine and fatal severe cutaneous adverse reactions – a review of spontaneous reports |
| title_fullStr | Collaboration in pharmacovigilance: lamotrigine and fatal severe cutaneous adverse reactions – a review of spontaneous reports |
| title_full_unstemmed | Collaboration in pharmacovigilance: lamotrigine and fatal severe cutaneous adverse reactions – a review of spontaneous reports |
| title_short | Collaboration in pharmacovigilance: lamotrigine and fatal severe cutaneous adverse reactions – a review of spontaneous reports |
| title_sort | collaboration in pharmacovigilance lamotrigine and fatal severe cutaneous adverse reactions ndash a review of spontaneous reports |
| topic | Anti-epileptic drug pharmacovigilance Stevens-Johnson syndrome toxic epidermal necrolysis Drug Reaction with Eosinophilia and Systemic Symptoms |
| url | https://www.dovepress.com/collaboration-in-pharmacovigilance-lamotrigine-and-fatal-severe-cutane-peer-reviewed-article-TCRM |
| work_keys_str_mv | AT brickeln collaborationinpharmacovigilancelamotrigineandfatalseverecutaneousadversereactionsndashareviewofspontaneousreports AT shaikhh collaborationinpharmacovigilancelamotrigineandfatalseverecutaneousadversereactionsndashareviewofspontaneousreports AT kirkhama collaborationinpharmacovigilancelamotrigineandfatalseverecutaneousadversereactionsndashareviewofspontaneousreports AT daviesg collaborationinpharmacovigilancelamotrigineandfatalseverecutaneousadversereactionsndashareviewofspontaneousreports AT chalkerm collaborationinpharmacovigilancelamotrigineandfatalseverecutaneousadversereactionsndashareviewofspontaneousreports AT yoshidap collaborationinpharmacovigilancelamotrigineandfatalseverecutaneousadversereactionsndashareviewofspontaneousreports |